Dr. Freitag has held senior clinical development and medical leadership positions across global pharmaceutical companies and emerging biotechnology organizations. Most recently, he served as Chief Medical Officer at Azafaros, a biotechnology company focused on developing treatments for rare genetic disorders. Previously, he served as Chief Medical Officer at Dynacure, where he was responsible for medical and regulatory strategy, including clinical development of the company's lead investigational therapy for centronuclear myopathies, a group of rare inherited neuromuscular disorders. Earlier in his career, Dr. Freitag led clinical research and development at Debiopharm International, overseeing international drug development programs spanning Phase 1 through Phase 3 clinical trials. He also held senior leadership roles at BTG plc, including responsibility for global clinical development, and served as Vice President of Global Clinical Development and Innovation at Shire. He began his pharmaceutical industry career at Hoffmann-La Roche, where he led teams in pharmacovigilance and medical affairs. Dr. Freitag earned his medical degree from Kiel University in Germany.
